Immunotherapy

Verify with FDA CVM →

414 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
414
Total Reports
24
Deaths Reported
580.0%
Death Rate

Active Ingredients

Immunotherapy

Administration Routes

UnknownOralSublingualParenteralSubcutaneousOtherIntradermalTransdermal

Species Affected

Dog 394
Cat 20

Most Affected Breeds

Retriever - Labrador 55
Retriever - Golden 29
Shepherd Dog - German 23
Terrier - Bull - American Pit 21
Bulldog - French 16
Bulldog 14
Terrier - Yorkshire 14
Domestic Shorthair 12
Terrier - West Highland White 11
Shih Tzu 10

Most Reported Reactions

Lack of efficacy - NOS 61
Other abnormal test result NOS 43
Vomiting 38
INEFFECTIVE, ATOPY CONTROL 37
INEFFECTIVE, LOSS OF EFFECT 35
Lethargy (see also Central nervous system depression in 'Neurological') 34
Diarrhoea 28
Leucopenia NOS 23
Neutropenia 22
Elevated alanine aminotransferase (ALT) 19
Skin disorders NOS 18
Death by euthanasia 17

Outcome Breakdown

Ongoing
256 (61.8%)
Outcome Unknown
70 (16.9%)
Recovered/Normal
60 (14.5%)
Euthanized
17 (4.1%)
Died
7 (1.7%)
Recovered with Sequela
4 (1.0%)

Data Summary

Metric Value
Total adverse event reports 414
Reports involving death 24
Case-fatality rate (reported events) 580.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Immunotherapy Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 414 adverse event reports referencing Immunotherapy, including 24 reports in which the animal died — a 580.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Immunotherapy. Reported administration routes include Unknown, Oral, Sublingual, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Immunotherapy reports are Dog (394 reports), Cat (20 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (55), Retriever - Golden (29), Shepherd Dog - German (23) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Immunotherapy are Lack of efficacy - NOS (61), Other abnormal test result NOS (43), Vomiting (38), INEFFECTIVE, ATOPY CONTROL (37). Of the 414 reports with a coded outcome, Ongoing is the leading category at 61.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Immunotherapy.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial